ASH 2022 | The impact of cytogenetics on treatment decisions in AML
In this video, Onyee Chan, MD, Moffitt Cancer Center, Tampa, FL, discusses the impact of cytogenetics on treatment decisions in acute myeloid leukemia (AML), highlighting various treatment approaches that may be used in patients. Dr Chan explains that a hypomethylating agent (HMA)-venetoclax combination should be considered for patients with complex cytogenetics instead of traditional intensive chemotherapies, while the addition of gemtuzumab ozogamicin may be considered for patients with core binding factor (CBF) AML. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Syntrix Pharmaceuticals: Research Funding.
